Sunflower Pharmaceutical Group Co., Ltd. Class A
SSZSE:00273711.24
CNY
+0.13
(+1.17%)
ISIN
CNE100001WT7
Return %
Stock
S&P 500
1Y
-27.95
13.14
3Y
-51.13
80.78
5Y
-19.54
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jian Zhong Zhou
- Full Time Employees
- 5,025
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 18, Donghu Road Harbin HL China 150078
- IPO Date
- Dec 30, 2014
- Website
- kuihuayaoye.com
- Similar Companies
- Business
- Sunflower Pharmaceutical Group Co.,Ltd is a pharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of Chinese patent medicines, chemical and biological medicines, and healthcare products. Its product portfolio encompasses various therapeutic areas including pediatrics, gynecology, digestive system, respiratory and cold, rheumatic bone disease, cardiovascular and cerebrovascular diseases, supplements, antibiotics, and children's medicinal products. The company markets its products mainly under the Sunflower and Little Sunflower brands. Founded in 2005, Sunflower Pharmaceutical Group is headquartered in Harbin, China, and operates several state-of-the-art manufacturing facilities compliant with international quality standards. The company’s main products include liver protection tablets, Weikangling capsules, pediatric pulmonary fever cough and asthma oral solutions, pediatric phlegm relief granules, pediatric aminophenol and huanamine granules, and other branded OTC products. It focuses on both generic and innovative pharmaceuticals, with a significant presence in cardiovascular, oncology, infectious diseases, and chronic disease segments. Sunflower Pharmaceutical has a robust R&D pipeline, filed 12 new patents in 2023, and invests heavily in research and development, with a budget exceeding $50 million as of recent reports. Recent major changes include strategic expansion into new international markets, particularly in Southeast Asia and Europe, contributing to increased international sales by about 20%. The company reported record revenue growth of approximately 15% year-over-year, reaching about $500 million in total sales with a corresponding increase in net profit. It has recently received registration certificates for new products such as fexofenadine hydrochloride oral suspension, ibuprofen suspension, and ursodeoxycholic acid capsules. It also announced plans to invest around 10 million yuan to establish a wholly-owned subsidiary and continues to expand its product pipeline with 15 new drugs expected in clinical trials. Sunflower Pharmaceutical is further advancing its business strategy with a focus on innovation, sustainability, and digital health technology, including integrating telehealth services and enhancing IT systems with planned investments of $15 million in digital technologies for market expansion and improved patient support. Sunflower Pharmaceutical Group targets a 30% reduction in carbon emissions by 2025 and aims to increase its domestic market share from 8% to 10% through expanded distribution channels and partnerships. Its investment in sustainability includes environmentally friendly packaging and optimizing manufacturing processes. The company’s mission centers on high-quality pharmaceutical products, patient outcomes, and customer satisfaction, maintaining an 87% customer satisfaction score with improved patient adherence through education and support initiatives aimed at over 100,000 patients. Overall, Sunflower Pharmaceutical Group combines innovative drug development, strategic market expansion, and sustainability initiatives to strengthen its position in the pharmaceutical industry domestically and internationally.